Gamida Cell looks to get $22M+ on its public offering launch; Esperion signs co-promotion pact with Currax
The cell therapy biotech Gamida Cell went forward with its public offering on the back of FDA approval for Omisirge (omidubicel-onlv), its allogeneic cord blood-based cell therapy used to quicken the recovery of white blood cells for cancer patients.
On Wednesday, Gamida Cell announced that it is selling 17.5 million shares in its public offering, and it expects to bring in around $22.8 million in total before expenses. The offer is expected to close on Apr. 21.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.